GlassScriptPhysician profile
Aaron David Jarrett
NPI 1689017394
$7,598.82
in general payments reported to CMS, 2019-2025
53 companies · $1,322 in 2025
The $1,322 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.46 · 2020: $553 · 2021: $1,443 · 2022: $1,288 · 2023: $1,467 · 2024: $1,501 · 2025: $1,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,289.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,184.47 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $935.62 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $728.45 | 2021-2025 | |
| Amgen INC. | $669.62 | 2020-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $601.63 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $446.10 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $352.77 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $323.40 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $200.57 | 2019-2023 | Spravato |
| Astellas Pharma US INC | $184.71 | 2023-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $158.59 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $145.04 | 2021-2025 | |
| Amarin Pharma, INC. | $137.87 | 2020-2021 | |
| Exact Sciences Corporation | $110.17 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Philips North America LLC | $103.69 | 2021-2023 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Jarrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.